Bragar Eagel & Squire, P.C. Ongoing Inquiry into AlloVir, Inc. for the Benefit of Long-Term Shareholders
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 16 2025
0mins
Should l Buy ?
Source: Globenewswire
Investor Alert: Bragar Eagel & Squire, P.C. is investigating potential claims against AlloVir, Inc. (NASDAQ:ALVR) for long-term stockholders who may have suffered losses between March 22, 2022, and December 21, 2023, following a class action complaint filed on March 19, 2024.
Allegations of Misconduct: The complaint alleges that AlloVir's board made false statements regarding the efficacy of its posoleucel Phase 3 studies, which were ultimately discontinued due to concerns about meeting primary endpoints, leading to a significant drop in the company's stock price.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
